Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Self-Selection Study Guidance Calls For Complex Questions

This article was originally published in The Tan Sheet

Executive Summary

Final guidance on Rx-to-OTC self-selection studies makes space for investigation of novel switches under NSURE by recommending researchers ask complex questions that “involve a higher level of understanding” of multiple label elements at once.

You may also be interested in...



In Switch Label Studies, FDA Carefully Reads Data On Low-Literacy Consumers

Switch sponsors should include low-literacy subjects in label comprehension studies to address the “real risk” of taking an Rx product OTC, says a CDER Division of Nonprescription Drug Products social scientist. Self-selection studies similarly should include at-risk consumer populations.

In Switch Label Studies, FDA Carefully Reads Data On Low-Literacy Consumers

Switch sponsors should include low-literacy subjects in label comprehension studies to address the “real risk” of taking an Rx product OTC, says a CDER Division of Nonprescription Drug Products social scientist. Self-selection studies similarly should include at-risk consumer populations.

FDA Expects OTC Switch Self-Selection Studies To Probe Consumer Thinking

A draft guidance on designing self-selection studies in support of Rx-to-OTC switches reflects FDA’s interest in drilling down for greater insight into consumers’ thought processes.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel